Dexmedetomidine in Suprazygomatic maxillary nerve block in cleft palate surgery

Suprazygomatic maxillary nerve block in cleft palate surgery: the efficacy of adding Dexmedetomidine to bupivacaine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201703002080167

Enrollment

Registered

2017-03-07

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery cleft palate surgery

Interventions

bilateral suprazygomatic maxillary block with 0.15 ml per kg 0.25 percent bupivacaine only

suprazygomatic maxillary block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: infants of American Society of Anesthesiologist (I, II), aged from 6 month to 5 year of both sex undergoing cleft palate repair will be enrolled in the study

Exclusion criteria

Exclusion criteria: The lack of parental consent, allergy to local anesthetic, cutaneous infection or wound close to the puncture point

Design outcomes

Primary

Measure	Time frame
Postoperative pain	—

Secondary

Measure	Time frame
Time to feed after tracheal extubation ;Side effects	—

Countries

Egypt

Contacts

Public ContactSameh Abd Elkhalik

lecturer of anesthesia and ICU

dr_sameh_100@yahoo.com0201002977048

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026